CATO SMS and Pharm-Olam Merge
Research Triangle Park, N.C.-based CATO SMS and Bracknell, U.K.-headquartered Pharm-Olam, both providers of specialized clinical research services, announced today that they are merging to form a leading global biopharmaceutical services organization uniquely positioned to serve the growing number of small and mid-sized companies developing complex therapies.
Although smaller businesses currently account for nearly 70% of the biopharmaceutical industry’s intellectual property, they have often found it challenging to receive the full attention of senior resources required to effectively design and manage clinical studies. CATO SMS and Pharm-Olam are joining forces to address this gap and serve the specific needs of small and mid-sized businesses.
Read more about the merge here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
